A Year in Patents - Part 3/4: The Procedures of International Patent Prosecution

​
September 5, 2023

Dr Girish Nivarti joined EIP's London office in October 2022. In this four-part series, he chronicles his first year as a trainee patent attorney.

A mulberry tree near my current home reminds me of my childhood. The smell, texture, and taste of mulberries (शहतूत in Hindi, pronounced shah-toot) evoke some of my earliest memories from the Himalayan region of Jammu & Kashmir. I have lived in the UK for long enough to feel at home, yet, when I find myself missing India, that mulberry tree becomes my source of solace. Only a small minority of patent professionals in the UK are of South Asian heritage. Thankfully, the lack of diversity in the field has been recognised: the professional network IP Inclusive, for instance, supports initiatives such as "IP & ME," a campaign that assists and inspires ethnic minorities to enter and practice within IP professions. It gives me joy and pride to see individuals of South Asian and other minority backgrounds in leadership positions in my own firm.

In addition to the geographies that shape people's lives, the mulberry tree makes me think of the geographies of intellectual property protection. The influence that the geographical features of a given region have on the quality of a final product sometimes directly inform the product's IP protection. Various international treaties define Geographical Indications (GIs) as a category of protection to products with a specified geographical origin and with qualities or a reputation linked to that origin. In India, traditional sarees made from mulberry silk often have geographically specific weaving patterns, brocades, and motifs, such as those in the Kanchipuram or Banarasi style, and are protected by GIs. Interestingly, trademarks are not the appropriate registration for geographically specific products, because trademarks need to be, among other things, non-descriptive; place names, obvious indicators of geographic origin, are considered descriptive. Thus, products such as champagne, from Champagne, France, or parmesan cheese, from Parma and Reggio Emilia in Italy, are not protected under trademark law but as Products of Designated Origin, a type of Geographical Indication of the European Union.

At the end of the British mulberry season, in September, I will begin studying for a Postgraduate Certificate (PGCert) in Intellectual Property Law at the Queen Mary University (QM) in London. The course is designed to provide trainees with robust basic knowledge on legal topics ranging from fundamental concepts in English law to specialist topics relating to patents and other aspects of intellectual property law. The QM course is one of several routes by which trainees to progress to the UK Final Exams set by the Patent Examination Board (PEB). Alternative routes include other PEB-accredited courses such as those run by Brunel University and Bournemouth University, and a set of Foundation Exams set by the PEB itself. The QM course is a popular choice for trainees based in London, and most candidates enrol on the course a year or so into their traineeship. It has become common practice for firms to sponsor trainees' attendance of the course, which runs from September to Christmas, with exams soon after, in January.

I am often asked whether training as a patent attorney in London restricts me to practice in the UK. The impacts of Brexit have certainly not left the legal sphere unaffected, but a comforting fact is that the UK remains a signatory of the European Patent Convention (EPC). Membership of the EPC means that the UK remains a state where patents granted by the European Patent Office can be validated. It is standard practice to qualify as both a Chartered (UK) Patent Attorney and a European Patent Attorney in parallel. Although the routes to qualification are separate, there is overlap in the curriculum: candidates who have passed certain European exams are exempt from taking the corresponding UK Final Exams. In recent years, the format of the European exams has been debated frequently. What should the exams test exactly? Should the examined content pertain more to historical and theoretical knowledge in the field, or to scenarios related to day-to-day practice? Notwithstanding its continuing membership of the EPC, as a non-member of the EU, Britain has had to withdraw its membership of the Unified Patent Court (UPC), the transnational court which opened in June this year. Maintaining branch offices—or at least collaborations with partners—in EU countries allows UK-headquartered firms like mine to participate in litigating cases at the UPC.

Qualifying as a dual UK and European patent attorney is valuable, as both jurisdictions are important commercial markets for innovative companies around the world. While various international treaties such as the Paris Convention and the Patent Cooperation Treaty (PCT) have considerably harmonised patent laws around the world, they have not diminished the value of specialised qualified patent attorneys, whose expertise is crucial in navigating the significant jurisdictional differences in the rules and procedures of patent prosecution in various places. On the one hand, a UK patent firm may assist in prosecuting patents entering the UK and Europe after being drafted in another country, and on the other hand may instruct the filing and prosecution of patents internationally for inventions originating in the UK. My firm, EIP, specialises in direct client work, meaning that we have direct contact with inventors and/or their employers, who may be based in the UK, Europe, or the US, which is made possible by the firm having branches in the US, UK, Germany, and Sweden.

The close-knit nature of British and European patent statutes and conventions means that patent attorneys in one region a close watch over movements in the other. For instance, as a trainee working on mathematical and software inventions in London, I frequently study and analyse trends in the decisions made by the EPO. I have found that understanding trends in appeals is particularly valuable for forecasting future patterns of examination and decision-making. At the EPO, appeals against decisions of technical merit are passed to the Technical Boards of Appeal, each consisting of a group of reviewers specialised in the technical field of the invention. For cases with particularly important legal implications, the Technical Boards may raise questions to the Enlarged Board of Appeal, the highest level of authority within the EPO. One recent decision on an appeal concerned an area related to my own research expertise, setting a precedent for the patentability of computer simulations. Not unlike science, law also evolves through the repeated application of established principles, until a disruptive case comes along to challenge prior understanding and thereby motivates novel interpretations.

Of the various jurisdictions in the world, Europe is considered by many to be one of the most challenging to patent in. The reputation stems from the fact that the EPO applies strict criteria as to the type of innovation that is patentable, and that which is not. These criteria frame prosecution work, that is, the process of preparing responses to objections raised by the examiner. Prosecution often involves several rounds of back and forth between attorney and examiner, with arguments drawing from combinations of legal interpretation, logical reasoning, and scientific understanding. In a recent case I worked on, the patent examiner identified a pure mathematical paper which appeared to dispute the patentability of the application that had been filed. My task, then, was to dig deep into the concepts and proofs explained in the paper, in order to prepare a counterargument and overcome the objections raised by the examiner. The task was hugely enjoyable given my longstanding fascination with pure mathematics. Previously, as an academic working on astrophysical fluid dynamics, pure mathematical problems were limited to fleeting conversations over tea with colleagues; now, as a trainee patent attorney, I enjoy the challenge of engaging with them head-on.

Another difference between the academic researcher and the patent attorney working on prosecution is that the latter is fungible. Cases are regularly passed on between attorneys for reasons ranging from workload management to the expertise demanded by a given case at a given time. For the workflow to be seamless between cases, a record of prosecution history must be carefully maintained. Symphonic collaboration between IT staff and the records management teams is essential to ensure both that information flows freely and reliably across the firm and that it remains secure. The contributions of paralegals, whose many tasks include assisting patent attorneys in maintaining records of their current cases and imminent deadlines, are also hugely valuable. For instance, paralegals manage much of the correspondence with foreign attorneys and clients; a patent attorney's day-to-day work is simply unimaginable without the support of paralegals.

Too bad paralegals can't assist trainees with their qualifying examinations—otherwise, I look forward to beginning my studies at QM next month.

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​